Home/Pipeline/NUZ-001

NUZ-001

Amyotrophic Lateral Sclerosis (ALS)

Phase 2/3 (Platform Trial)Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 2/3 (Platform Trial)

Status

Active

Company

Neurizon Therapeutics, Neurizon Therapeutics, Neurizon Therapeutics, Neurizon Therapeutics

About Neurizon Therapeutics

Australian biotech repurposing S‑Monepantel to treat ALS and other neurodegenerative disorders.

View full company profile

About Neurizon Therapeutics

Australian biotech repurposing S‑Monepantel to treat ALS and other neurodegenerative disorders.

View full company profile

About Neurizon Therapeutics

Australian biotech repurposing S‑Monepantel to treat ALS and other neurodegenerative disorders.

View full company profile

About Neurizon Therapeutics

Australian biotech repurposing S‑Monepantel to treat ALS and other neurodegenerative disorders.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Alzheimer's Disease Parkinson's Disease Huntington's Disease

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active
NG CELL	NeuroGenesis Bio	Phase 2	Active
NP001	Neuvivo	Phase 3	Active